Publicaciones en colaboración con investigadores/as de University of Sydney (7)

2024

  1. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Lucitanib for the treatment of HRþ/HER2- Metastatic breast cancer: Results from the multicohort phase II FINESSE study

    Clinical Cancer Research, Vol. 26, Núm. 2, pp. 354-363

  2. Pembrolizumab for early triple-negative breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 9, pp. 810-821

2019

  1. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study

    Annals of Oncology, Vol. 30, Núm. 3, pp. 397-404

2014

  1. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: The neuromodulation appropriateness consensus committee

    Neuromodulation, Vol. 17, Núm. 6, pp. 515-550